Last reviewed · How we verify

Renin-angiotensin sytem blockers

Fondazione Schena · FDA-approved active Small molecule Quality 3/100

Renin-angiotensin sytem blockers is a Small molecule drug developed by Fondazione Schena. It is currently FDA-approved. Also known as: Ramipril, lisinopril, losartan.

At a glance

Generic nameRenin-angiotensin sytem blockers
Also known asRamipril, lisinopril, losartan
SponsorFondazione Schena
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Renin-angiotensin sytem blockers

What is Renin-angiotensin sytem blockers?

Renin-angiotensin sytem blockers is a Small molecule drug developed by Fondazione Schena.

Who makes Renin-angiotensin sytem blockers?

Renin-angiotensin sytem blockers is developed and marketed by Fondazione Schena (see full Fondazione Schena pipeline at /company/fondazione-schena).

Is Renin-angiotensin sytem blockers also known as anything else?

Renin-angiotensin sytem blockers is also known as Ramipril, lisinopril, losartan.

What development phase is Renin-angiotensin sytem blockers in?

Renin-angiotensin sytem blockers is FDA-approved (marketed).

Related